We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics


EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App

Euroimmun and Xpedite Diagnostics Partner to Offer Faster, Easier Protocols for DNA Extraction at POC

By LabMedica International staff writers
Posted on 19 Dec 2023
Print article
Image: Current users of EUROArray diagnostic platform will be offered EUROArray SwiftX-traction Kit for rapid manual DNA extraction (Photo courtesy of EUROIMMUN)
Image: Current users of EUROArray diagnostic platform will be offered EUROArray SwiftX-traction Kit for rapid manual DNA extraction (Photo courtesy of EUROIMMUN)

EUROIMMUN (Lübeck, Germany) and Xpedite Diagnostics (Hallbergmoos, Germany) have entered into a strategic partnership for offering faster and easier protocols for DNA extraction at the point-of-care. Current users of the EUROArray diagnostic platform will now have access to the EUROArray SwiftX-traction Kit designed for rapid manual DNA extraction. EUROArray SwiftX-traction significantly reduces the complexity as well as processing time of the DNA extraction. It can extract DNA from different challenging sample types using just a few steps that take less than 30 minutes.

The new extraction method is currently being validated in combination with various CE-marked EUROArray products. Xpedite Diagnostics aims to soon register the extraction kit itself as a CE-IVD device under the European IVD Regulation 2017/746. Xpedite Diagnostics’ partnership with EUROIMMUN demonstrates its technical leadership in offering high-performing and user-friendly nucleic acid extraction solutions. This, combined with its strong expertise in quality management and regulatory affairs, makes Xpedite Diagnostics well-positioned to act as a reliable and efficient contract developer as well as manufacturer for other IVD companies.

“EUROArray SwiftX-traction was tailored specifically to the needs of users of the EUROArray diagnostic platform and is based on our SwiftX Toolbox,” said Dr. Andy Wende, CEO and Head of R&D at Xpedite Diagnostics GmbH. “The development was finished in only a few months and will result in a CE-IVD marked DNA extraction kit. It merges several advantages such as high sensitivity, short workflows, and improved usability. EUROArray SwiftX-traction will enhance customer satisfaction and acceptance, ultimately leading to a better sales position of the EUROArray diagnostic platform in the segments Dermatomycosis, STI testing, and HPV typing.”

Related Links:
Xpedite Diagnostics 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic ELISA Workstation

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.